Drug Profile

UB VV100 with RACR-CD19 CAR T cells

Alternative Names: UB VV100; UB VV100 with RACR-CD19 CAR T cells - Umoja Biopharma; VivoVec UB VV100 with RACR-CD19 CAR T cells - Umoja Biopharma

Latest Information Update: 28 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Umoja Biopharma
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Oct 2025 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (IV)
11 Oct 2022 Umoja plans to file an IND application with the US FDA for Hematologic malignancies in 2023(Umoja pipeline; October 2022)
19 May 2022 Pharmacodynamics data from a preclinical study in Haematological malignancies released by Umoja Biopharma

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com